All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Oncology Drugs in Phase III Clinical Development in HONG KONG

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Hutchison China MediTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

US FDA Grants Fast Track Status to Chi-Med’s Fruquintinib for Colorectal Cancer

Contact the Supplier

Lead Product(s): Fruquintinib

Therapeutic Area: Oncology Product Name: HMPL-013

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 20, 2020

Details:

Fast Track Designation has been granted for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Hutchison China MediTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China

Contact the Supplier

Lead Product(s): Fruquintinib,Paclitaxel

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

FRUTIGA is a Phase III trial in China of fruquintinib in combination with paclitaxel (Taxol®) in the treatment of patients with advanced gastric adenocarcinoma or gastroesophageal junction (“GEJ”) adenocarcinoma who have progressed after first-line standard chemotherapy.

Hutchison China MediTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

Chi-Med's Surufatinib Bags US Fast Track Designations

Contact the Supplier

Lead Product(s): Surufatinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 17, 2020

Details:

The drug, a novel, oral angio-immuno kinase inhibitor, is being developed for patients who are unable to have surgery for these conditions.

Hutchison China MediTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine T...

Contact the Supplier

Lead Product(s): Surufatinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 20, 2020

Details:

The IDMC recommended that the study stops early as the pre-defined primary endpoint of progression free survival had already been met.